They require special attention in clinical weight management and early prevention and treatment of metabolic syndrome [i] , whereas the effective drug treatment options are limited
in Spain, its current prevalence ranges between 2833%11,12 and it is a recognized as a cardiovascular risk factor and increases the mortality in this population.1315 Furthermore, in patients with DM2 and advanced CKD there are limitations in the prescription of certain antihyperglycemic drugs (e.g., metformin or sulfonylureas) and there is an increased risk of hypoglycemia with antihyperglycemic treatment,16 a complication that is associated with increased cardiovascular risk17 and hinders the achievement of glycemic control targets
Until recently, the only officially approved oral version was Rybelsus the semaglutide formulation for type 2 diabetes
Insulin lowers blood sugar level and glucagon raises levels
The most successful racing pigeons are not those that have burned away every reserve of fat
9% Asian, 9% Asian/White, 82% White